-
61.发明公开트립토파닐 티알엔에이 합성효소를 유효성분으로 포함하는 감염성 염증 질환의 치료 또는 예방용 조성물 및 면역증강용 조성물 审中-实审用于治疗或预防感染性感染性炎症疾病和增强包含TRYPTOPHANYL-TRNA SYNTHETASE的免疫应答的组合物
公开(公告)号：KR1020160104587A
公开(公告)日：2016-09-05
申请号：KR1020160023593
申请日：2016-02-26
Applicant: 재단법인 의약바이오컨버젼스연구단 , 대전대학교 산학협력단
CPC classification number: A61K38/53 , A23L33/10 , A23L33/40 , A23V2002/00 , C12N9/00 , C12Y601/01002
Abstract: 본발명은트립토파닐티알엔에이합성효소(tryptophanyl-tRNA synthetase, TrpRS)를유효성분으로포함하는감염성염증질환의치료또는예방용조성물및 면역증강용조성물에대한것으로, 보다상세하게는트립토파닐티알엔에이합성효소를유효성분으로포함하는감염에의한염증성질환의예방또는치료용약학적조성물, 예방또는개선용식품용조성물, 및예방또는치료용수의학적조성물, 그리고트립토파닐티알엔에이합성효소를유효성분으로포함하는면역증강용조성물에대한것이다. 본발명의조성물은특히선천면역반응을활성화시킴으로써박테리아및 바이러스등의감염을초기단계에억제하여박테리아및 바이러스등의감염이유발하는인간과동물의질환을예방또는치료하는데유용하게사용될수 있다.
Abstract translation: 本发明涉及用于治疗或预防感染性炎性疾病的组合物和用于增强免疫应答的组合物，其包含色氨酰-tRNA合成酶（TrpRS）作为活性成分。 更具体地，本发明涉及药物组合物，食物组合物和治疗性兽医组合物，其全部包括作为治疗或预防感染性炎性疾病的活性成分的色氨酰-tRNA合成酶（TrpRS），以及包含 色氨酰-tRNA合成酶（TrpRS）作为增强免疫应答的活性成分。 通过激活特定的先天免疫应答，本发明的组合物可以在早期阶段抑制细菌和病毒感染，因此可有益地用于预防或治疗由人和动物中的细菌和病毒感染引起的疾病。
-
公开(公告)号：KR1020160083828A
公开(公告)日：2016-07-12
申请号：KR1020160080285
申请日：2016-06-27
Applicant: 재단법인 의약바이오컨버젼스연구단
Abstract: 본발명은 3차원적환경에서배양된암 세포의모양관찰, 인바도포디아(invadopodia) 형성및 전이에관련된단백질의활성, 발현및 발현위치변화, 세포외기질의분해측정을이용한암 세포의이동, 침윤및 전이성모니터링, 및암 전이억제제스크리닝방법에관한것으로, 보다구체적으로 3차원콜라겐겔 환경내에서배양된세포에서 c-Jun 인산화의감소가 snail1의발현증가및 코르탁틴(cortactin) 발현감소를유발하였고, 이러한단백질들간의발현조절관계는환자로부터수득한유방암세포조직에서도동일함을확인하였다. 또한, 3차원적콜라겐겔 환경내의유방암세포에 JNK 억제제를처리하였을때, 세포의모양이길어지고, 세포및 세포외기질의접촉부분이밋밋해지고가늘어지며, 암세포의이동이감소하고, 단백질발현변화에있어서는 TGFβ1의발현증가, smad2 및 smad3의발현및 활성증가, snail1의발현증가및 코르탁틴의발현감소및 이에따른인바도포디아의형성저하를확인하였다. 또한, 3차원콜라겐겔 환경에서코르탁틴외에도 MT1-MMP가다른인바도포디아마커로사용될수 있고, 이는 JNK 억제가코르탁틴의발현을감소시키고, snail1의발현을증가시키면서동시에 MT1-MMP의위치및 역할에부정적영항을미쳐인바도포디아의형성을억제하며, 콜라겐겔 기질의분해능을억제하는것을확인함으로써암 세포의이동, 침윤, 전이성및 전이정도를모니터링하는방법및 암전이억제제의스크리닝방법으로사용할수 있고, 이는약물개발에필요한전임상실험시 저비용고효율의부가가치를창출할수 있는스크리닝방법중의하나로유용하게사용될것이다.
Abstract translation: 本发明涉及使用在3D胶原凝胶环境中培养的细胞监测癌细胞转移的方法。 该方法包括以下步骤：1）通过在培养容器中使用3D培养环境培养癌细胞; 2）测量形状的变化，侵袭过程的形成和降解，运动的活动，渗透和转移相关蛋白，表达以及细胞外基质的表达位置或降解程度的变化 的培养的癌细胞。 本发明提供了监测癌细胞的运动，渗透，转移和转移程度的方法。
-
公开(公告)号：KR1020160017374A
公开(公告)日：2016-02-16
申请号：KR1020140100605
申请日：2014-08-05
Applicant: 고려대학교 산학협력단 , 재단법인 의약바이오컨버젼스연구단
Abstract: 본발명은미세소포체분리방법및 미세소포체분리장치에관한것으로, 본원발명의명세서에기재된 (a) 내지 (d) 단계를포함하는미세소포체분리방법및 이를이용한미세소포체분리장치는, 원심분리법이나특정항체에의존하지않고도생물학적시료로부터미세소포체를높은수준으로수득하는데매우효과적이며, 또한실험자가원하는특정미세소포체만을별도의추가분류과정없이선택적으로분리할수 있는것이특징이다.
Abstract translation: 本发明涉及分离微泡的方法和用于分离微泡的装置。 包含步骤（a）至步骤（d）的微泡分离方法和本发明说明书中公开的分离微囊的装置有效地从生物样品获得微泡，而不依赖于离心分离方法或 并且还选择性地分离测试者所需的特定微泡，而不需要额外的分类过程。
-
公开(公告)号：KR101580681B1
公开(公告)日：2015-12-29
申请号：KR1020130021769
申请日：2013-02-28
Applicant: 재단법인 의약바이오컨버젼스연구단
Abstract: 본발명은글라이실-tRNA 합성효소(GRS)를포함하는마이크로베지클의제조방법에관한것으로, 더욱상세하게는글라이실-tRNA 합성효소를포함하는마이크로베지클의제조방법및 상기제조방법으로제조된마이크로베지클과이의용도에관한것이다. 본발명의제조방법으로제조한 GRS를포함하는마이크로베지클은암을치료하는데효과적이다.
-
公开(公告)号：KR1020130118612A
公开(公告)日：2013-10-30
申请号：KR1020120041623
申请日：2012-04-20
Applicant: 재단법인 의약바이오컨버젼스연구단
IPC: C07D213/75 , C07D215/38 , A61K31/435 , A61K31/44 , A61K31/47 , A61K31/4706
CPC classification number: C07D215/38 , A61K31/435 , C07D213/75 , A61K31/44 , A61K31/47 , A61K31/4706
Abstract: PURPOSE: A novel aminopyridine derivative is provided to suppress the activity of AIMP2-DX2 which is a new target of an anticancer agent and to effectively induce apoptosis of cancer cells, thereby effectively preventing and treating cancer. CONSTITUTION: An aminopyridine derivative of chemical formula 1 or a pharmaceutically acceptable salt thereof is provided. A pharmaceutical composition for preventing or treating cancer contains the aminopyridine derivative of chemical formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient. The derivative is selected among ethyl 3-[(5-chloropyridine-2-yl)amino]-2-methyl-3-oxopropanoate, ethyl 3-[(6-methylpyridine-2-yl)amino]-3-oxopropanoate, ethyl 3-oxo-3-(quinoline-3-ylamino) propanoate, ethyl 3-[(3,6-dimethylpyridine-2-yl)amino]-3-oxopropanoate, ethyl 3-[(4-hydroxypyridine-2-yl)amino]-3-oxopropanoate, ethyl 2-methyl-3-oxo-3-(quinoline-3-ylamino) propanoate, ethyl 2-methyl-3-[(6-methylpyridine-2-yl)amino]-3-oxopropanoate, and ethyl 3-[(5-chloropyridine-2-yl)amino]-3-oxopropanoate.
Abstract translation: 目的：提供一种新的氨基吡啶衍生物，以抑制作为抗癌剂新靶标的AIMP2-DX2的活性，有效诱导癌细胞凋亡，从而有效预防和治疗癌症。 构成：提供化学式1的氨基吡啶衍生物或其药学上可接受的盐。 用于预防或治疗癌症的药物组合物含有化学式1的氨基吡啶衍生物或其药学上可接受的盐作为活性成分。 该衍生物选自3 - [（5-氯吡啶-2-基）氨基] -2-甲基-3-氧代丙酸乙酯，3 - [（6-甲基吡啶-2-基）氨基] -3-氧代丙酸乙酯，乙基 3-（3-喹啉-3-基氨基）丙酸乙酯，3 - [（3,6-二甲基吡啶-2-基）氨基] -3-氧代丙酸乙酯，3 - [（4-羟基吡啶-2-基） 氨基] -3-氧代丙酸乙酯，2-甲基-3-氧代-3-（喹啉-3-基氨基）丙酸乙酯，2-甲基-3 - [（6-甲基吡啶-2-基）氨基] -3-氧代丙酸乙酯 ，和3 - [（5-氯吡啶-2-基）氨基] -3-氧代丙酸乙酯。
-
Patent Agency Ranking
公开(公告)号：KR1020130032286A
公开(公告)日：2013-04-01
申请号：KR1020120105694
申请日：2012-09-24
Applicant: 재단법인 의약바이오컨버젼스연구단
IPC: C12N15/113 , G01N33/15 , C12N9/00 , G01N33/68
CPC classification number: G01N33/573 , C12N15/1137 , C12N2310/14 , C12Y601/01004 , G01N33/574 , G01N2800/044
Abstract: PURPOSE: A method for screening a therapeutic agent for mTORC1(mammalian target of rapamycin complex 1)-induced diseases is provided to control cell size, and to develop a novel therapeutic agent for treating cancer. CONSTITUTION: A method for screening a therapeutic agent for preventing and treating mTORC1-mediated diseases comprises: a step of contacting LRS(leucyl tRNA synthetase), RagD, and a test agent under the presence or absence of the therapeutic agent; a step of comparing the LRS and RagD binding under the presence or absence of the therapeutic agent; and a step of measuring binding change.
Abstract translation: 目的：提供用于筛选mTORC1（雷帕霉素复合物1的哺乳动物靶）诱导的疾病的治疗剂的方法以控制细胞大小，并开发用于治疗癌症的新型治疗剂。 构成：用于筛选预防和治疗mTORC1介导的疾病的治疗剂的方法包括：在存在或不存在治疗剂的情况下使LRS（亮氨酰tRNA合成酶），RagD和试验剂接触的步骤; 在存在或不存在治疗剂的情况下比较LRS和RagD结合的步骤; 和测量绑定变化的步骤。
-
公开(公告)号：KR1020130016134A
公开(公告)日：2013-02-14
申请号：KR1020120085685
申请日：2012-08-06
Applicant: 재단법인 의약바이오컨버젼스연구단
IPC: C07C233/07 , C07C233/09 , C07C233/15 , C07C233/25 , C07C233/27 , A61K31/167
CPC classification number: C07C235/74 , A61K31/167 , A61P35/00 , C07C233/04 , C07C233/07 , C07C233/09 , C07C233/15 , C07C233/25 , C07C233/27 , C07C235/76 , C07C2603/24
Abstract: PURPOSE: An aniline derivative is provided to effectively derive the death of cancer cells by reducing the activity of AIMP2-DX2 which is a target for a new anticancer drug. CONSTITUTION: An aniline derivative is indicated in chemical formula 1. In the chemical formula 1: each of R1-R5 is selected from hydrogen, C1-C4 linear, branched or cyclic alkyl, halogen, alkoxy, and hydroxy; R6 is -CO-CH=CH-COR7 or -CO-CHR9-COR8; R7 is a hydroxy or a functional group indicated in chemical formula 1-a; R8 is a C1-6 alkoxy or a functional group indicated in chemical formula 1-b; R9 is hydrogen or a C1-6 alkyl; and each of R10-R14 is selected from hydrogen, methyl, halogen, and methoxy.
Abstract translation: 目的：提供苯胺衍生物，通过降低作为新抗癌药物靶标的AIMP2-DX2的活性来有效地导致癌细胞的死亡。 化学式1表示苯胺衍生物：化学式1：R1-R5各自选自氢，C1-C4直链，支链或环状烷基，卤素，烷氧基和羟基; R6是-CO-CH = CH-COR7或-CO-CHR9-COR8; R7是化学式1-a所示的羟基或官能团; R8是C1-6烷氧基或化学式1-b表示的官能团; R9为氢或C1-6烷基; R 10 -R 14选自氢，甲基，卤素和甲氧基。
-
68.发明公开벤조헤테로사이클 유도체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 암 예방 및 치료용 조성물 有权用于预防和治疗包含苯唑酮衍生物或其药学上可接受的盐的癌症的药物组合物作为活性成分
公开(公告)号：KR1020110049364A
公开(公告)日：2011-05-12
申请号：KR1020090106350
申请日：2009-11-05
Applicant: 재단법인 의약바이오컨버젼스연구단
IPC: A61K31/4184 , A61K31/423 , A61K31/428 , A61P35/00
CPC classification number: A61K31/4184 , A61K31/423 , A61K31/428
Abstract: PURPOSE: A composition containing benzoheterocycle derivatives for preventing and treating cancer is provided to suppress cancer or tumor by inhibiting interaction of KRS and 67LR. CONSTITUTION: A pharmaceutical composition for preventing or treating cancer contains benzoheterocycle derivative of chemical formula 1 or pharmaceutically acceptable salt thereof as an active ingredient. In chemical formula 1, A is O, NH, or S; X is C or N; and R1 is hydrogen, non-substituted or halogen-substituted alkyl, alkoxy, halogen, nitro, or amine. The cancer is colon cancer, lung cancer, liver cancer, gastric cancer, bladder cancer, uterine cancer, brain cancer, or melanoma.
Abstract translation: 目的：提供含有用于预防和治疗癌症的苯并杂环衍生物的组合物，通过抑制KRS和67LR的相互作用来抑制癌症或肿瘤。 构成：用于预防或治疗癌症的药物组合物含有化学式1的苯并杂环衍生物或其药学上可接受的盐作为活性成分。 在化学式1中，A是O，NH或S; X为C或N; 并且R 1是氢，未取代或卤素取代的烷基，烷氧基，卤素，硝基或胺。 癌症是结肠癌，肺癌，肝癌，胃癌，膀胱癌，子宫癌，脑癌或黑素瘤。
-
公开(公告)号：KR102133929B1
公开(公告)日：2020-07-14
申请号：KR1020180069146
申请日：2018-06-15
Applicant: 재단법인 의약바이오컨버젼스연구단
IPC: A61K48/00 , A61K31/713 , A61K39/395 , G01N33/50
-
-
-
-
-
-
-
-
-
Search Results
147
records
(took 0.045 seconds)
